Autonomic Nervous System: Introduction

Correct Answer

B — Selective alpha-1 adrenergic receptor antagonist

Rationale

Prazosin is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on vascular smooth muscle and in the prostate, producing vasodilation and urethral relaxation. A selective beta-1 antagonist describes drugs such as metoprolol or atenolol. A muscarinic antagonist describes drugs such as atropine. An alpha-2 agonist describes drugs such as clonidine, which acts via a different receptor and produces opposite cardiovascular effects through a central mechanism.

Correct Answer

D — Muscarinic M3 receptor agonist

Rationale

Pilocarpine is a muscarinic M3 receptor agonist. M3 receptors mediate contraction of smooth muscle and secretion from glands, which accounts for pilocarpine's clinical effects — miosis and ciliary muscle contraction in the eye (used for glaucoma) and salivary stimulation (used for dry mouth in Sjogren syndrome). Pilocarpine does not act at nicotinic receptors, does not activate alpha-1 adrenergic receptors, and does not block muscarinic receptors.

Correct Answer

A — Cardioselective beta-1 adrenergic receptor antagonist

Rationale

Metoprolol is a cardioselective beta-1 adrenergic receptor antagonist — at therapeutic doses it preferentially blocks beta-1 receptors in the heart, slowing heart rate and reducing contractility, while having less effect on beta-2 receptors in the bronchi and peripheral vasculature. This selectivity distinguishes it from non-selective beta antagonists such as propranolol, which block both beta-1 and beta-2. Metoprolol does not block alpha-1 receptors and does not activate beta-2 receptors.

Correct Answer

C — Alpha-2 adrenergic receptor agonist

Rationale

Clonidine is an alpha-2 adrenergic receptor agonist. By activating alpha-2 receptors in the brainstem, it reduces central sympathetic outflow and lowers blood pressure and heart rate. An alpha-1 agonist such as phenylephrine would produce vasoconstriction and raise blood pressure. A beta-1 agonist such as dobutamine would increase heart rate and cardiac contractility. A muscarinic agonist such as bethanechol would produce parasympathetic effects at smooth muscle and glands.

Correct Answer

B — Selective beta-2 adrenergic receptor agonist

Rationale

Albuterol is a selective beta-2 adrenergic receptor agonist. Beta-2 receptors in bronchial smooth muscle mediate bronchodilation when activated, making albuterol effective as a rescue inhaler in asthma and chronic obstructive pulmonary disease. Its selectivity for beta-2 over beta-1 reduces but does not eliminate cardiac side effects at higher doses. A selective beta-1 agonist such as dobutamine acts on the heart. An alpha-1 agonist such as phenylephrine causes vasoconstriction. A muscarinic antagonist such as ipratropium produces bronchodilation by a different mechanism entirely.

Correct Answer

D — Non-selective muscarinic receptor antagonist

Rationale

Atropine is a non-selective muscarinic receptor antagonist — it blocks all five muscarinic subtypes (M1 through M5) without meaningful selectivity between them. Its diverse clinical effects reflect this non-selectivity: tachycardia (M2 block at sinoatrial node), dry mouth (M3 block at salivary glands), mydriasis (M3 block at iris sphincter), urinary retention (M3 block at bladder detrusor), and bronchodilation. Selective M2 antagonists and selective M3 antagonists exist as separate drug classes with more targeted profiles. Atropine does not block nicotinic receptors or adrenergic receptors.

Correct Answer

A — Gq activation → phospholipase C stimulation → inositol trisphosphate and diacylglycerol production → intracellular calcium release

Rationale

M1, M3, and M5 muscarinic receptors couple to Gq proteins. When activated, Gq stimulates phospholipase C, which cleaves phosphatidylinositol bisphosphate into two second messengers: inositol trisphosphate, which triggers release of calcium from the endoplasmic reticulum, and diacylglycerol, which activates protein kinase C. The resulting rise in intracellular calcium drives smooth muscle contraction and glandular secretion — explaining M3-mediated effects such as bronchoconstriction, bladder detrusor contraction, and salivary secretion. The Gi pathway with potassium channel opening describes M2 and M4 receptors. The Gs-cyclic adenosine monophosphate pathway describes beta-adrenergic receptors. Ligand-gated ion channel opening describes nicotinic receptors.

Correct Answer

C — Gi activation → adenylyl cyclase inhibition and potassium channel opening → hyperpolarization of sinoatrial node cells → slowed pacemaker rate

Rationale

M2 receptors couple to Gi proteins. When activated, Gi inhibits adenylyl cyclase, reducing cyclic adenosine monophosphate, and also directly activates a cardiac potassium channel called the acetylcholine-activated potassium channel. Potassium efflux through this channel hyperpolarizes sinoatrial node cells, making them slower to reach threshold for spontaneous depolarization and reducing the firing rate. This is the cellular basis of vagally induced bradycardia. The Gq-phospholipase C pathway describes M1, M3, and M5 receptors. The Gs pathway describes beta-adrenergic receptor activation, which increases heart rate. Ligand-gated sodium channels describe nicotinic receptors, which are not found at the sinoatrial node.

Correct Answer

B — Phenylephrine activates alpha-1 receptors on vascular smooth muscle, causing vasoconstriction and raising blood pressure; the baroreceptor reflex then activates the vagus nerve to slow heart rate

Rationale

Phenylephrine is a selective alpha-1 adrenergic receptor agonist. Alpha-1 receptors on vascular smooth muscle couple to Gq, activating phospholipase C and raising intracellular calcium, producing vasoconstriction. The resulting increase in blood pressure is detected by baroreceptors in the carotid sinus and aortic arch, which signal the brainstem to increase vagal tone and reduce sympathetic output. This reflex bradycardia is a baroreceptor-mediated response to the blood pressure rise — phenylephrine itself has no direct cardiac effect because the heart's rate-regulating receptors are predominantly beta-1 and M2, neither of which phenylephrine activates.

Correct Answer

D — Beta-2 selective agonists produce bronchodilation through airway beta-2 receptors while sparing beta-1 receptors in the heart, reducing the risk of tachycardia and arrhythmia

Rationale

The main advantage of beta-2 selective agonists over isoproterenol is reduced cardiac stimulation. Isoproterenol activates beta-1 receptors in the heart, producing tachycardia and arrhythmias in addition to bronchodilation. Albuterol and similar beta-2 selective agents preferentially activate beta-2 receptors in bronchial smooth muscle, producing the same degree of bronchodilation with less stimulation of cardiac beta-1 receptors. This separation of therapeutic effect from cardiac side effect is the clinical rationale for selectivity. Beta-2 selective agonists do not have greater intrinsic bronchodilatory efficacy than non-selective agents, do not interact with muscarinic receptors, and do not block alpha-1 receptors.

Correct Answer

A — The neuromuscular junction expresses nicotinic N-M receptors, which have different subunit composition and pharmacological sensitivity from the nicotinic N-N receptors at autonomic ganglia

Rationale

Both the neuromuscular junction and autonomic ganglia use nicotinic acetylcholine receptors, but the two locations express pharmacologically distinct subtypes. The N-M subtype at the motor endplate and the N-N subtype at ganglia differ in subunit composition, which produces different pharmacological sensitivities. Drugs can selectively target one subtype over the other — succinylcholine and non-depolarizing neuromuscular blockers act preferentially at N-M receptors, while ganglionic blockers such as trimethaphan act at N-N receptors. Autonomic ganglia do use nicotinic, not muscarinic, receptors at the ganglionic synapse. There is no blood-nerve barrier excluding succinylcholine from ganglia; the selectivity is pharmacological, not anatomical.

Correct Answer

C — Gi coupling → adenylyl cyclase inhibition → reduced cyclic adenosine monophosphate → decreased neuronal activity and reduced sympathetic outflow

Rationale

Alpha-2 adrenergic receptors couple to Gi proteins. Gi inhibits adenylyl cyclase, reducing cyclic adenosine monophosphate levels in the cell. In brainstem neurons that regulate sympathetic tone, this Gi-mediated inhibition reduces firing activity and lowers overall sympathetic outflow, decreasing heart rate and peripheral vascular resistance. Alpha-2 receptors on presynaptic sympathetic terminals use the same Gi mechanism to inhibit further norepinephrine release. Clonidine activates both central and peripheral alpha-2 receptors, but the central effect is the primary driver of antihypertensive action. Alpha-2 receptors do not couple to Gq, do not couple to Gs, and do not directly gate ion channels in the manner described.

Correct Answer

B — Chronic beta-1 blockade causes compensatory upregulation of beta-1 receptors; when the drug is stopped, these upregulated receptors respond to endogenous catecholamines with exaggerated tachycardia and hypertension

Rationale

When beta-1 receptors are chronically blocked, the cell compensates by increasing receptor number and sensitivity — a process called upregulation. This is the physiological counterpart to the downregulation that occurs with chronic agonist exposure. When the beta-blocker is abruptly stopped, the now-upregulated receptors are suddenly exposed to normal concentrations of circulating epinephrine and norepinephrine. Because there are more receptors than before treatment, the response is exaggerated — producing rebound tachycardia, hypertension, and in patients with coronary artery disease, potentially angina or myocardial infarction. Beta-blockers do not suppress norepinephrine synthesis, and the rebound tachycardia is not mediated by alpha-2 autoreceptors.

Correct Answer

D — Prolonged beta-2 receptor activation triggers G-protein-coupled receptor kinase phosphorylation of the receptor, recruiting arrestin proteins that uncouple the receptor from its G-protein and reduce signaling

Rationale

Repeated or sustained activation of beta-2 adrenergic receptors initiates rapid desensitization through a well-defined molecular sequence: G-protein-coupled receptor kinases phosphorylate the activated receptor, which creates a binding site for arrestin proteins. Arrestin binding physically uncouples the receptor from its Gs protein, preventing further adenylyl cyclase stimulation and cyclic adenosine monophosphate production even when albuterol is present. The receptor remains on the cell surface but can no longer signal effectively. With chronic overuse, receptor internalization and downregulation further reduce the number of functional receptors available. This is the pharmacological basis of the clinical guideline that overreliance on short-acting rescue inhalers signals inadequate disease control requiring step-up therapy. Adenylyl cyclase is not depleted, receptor type conversion does not occur, and muscarinic upregulation is not the mechanism here.

Correct Answer

C — Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck smooth muscle, reducing their tone and relieving the mechanical obstruction to urinary outflow

Rationale

Alpha-1 adrenergic receptors — particularly the alpha-1A subtype — are expressed in prostatic smooth muscle and the bladder neck, where sympathetic activation maintains resting tone. In benign prostatic hyperplasia, this tone contributes to the dynamic component of urinary obstruction. Tamsulosin selectively blocks alpha-1A receptors, relaxing prostatic and bladder neck smooth muscle and reducing outflow resistance. Its relative selectivity for alpha-1A over alpha-1B receptors in vascular smooth muscle accounts for its lower likelihood of causing orthostatic hypotension compared to non-selective alpha-1 blockers like prazosin. Tamsulosin does not activate muscarinic receptors, does not block beta-1 receptors, and does not inhibit phosphodiesterase-5.

Correct Answer

A — Chronic beta-1 blockade caused compensatory upregulation of beta-1 receptors; their sudden exposure to circulating catecholamines produces an exaggerated sympathomimetic response

Rationale

Prolonged beta-1 receptor blockade by metoprolol triggers a compensatory cellular response: the heart upregulates beta-1 receptor number and sensitivity in an attempt to restore normal signaling. When the drug is abruptly stopped, circulating epinephrine and norepinephrine encounter a larger-than-normal population of beta-1 receptors, producing an exaggerated response — tachycardia, palpitations, and in susceptible patients, angina or myocardial infarction. This is why beta-blockers must always be tapered gradually over one to two weeks rather than stopped abruptly. Metoprolol does not increase vagal tone or suppress norepinephrine synthesis, and alpha-1 receptors do not regulate cardiac rate in the same manner as beta-1 and M2 receptors.

Correct Answer

D — Sustained beta-2 receptor activation triggers G-protein-coupled receptor kinase phosphorylation and arrestin recruitment, uncoupling the receptor from Gs and reducing cyclic adenosine monophosphate production in response to albuterol

Rationale

Repeated or prolonged activation of beta-2 receptors initiates rapid desensitization. G-protein-coupled receptor kinases phosphorylate the activated receptor at specific serine and threonine residues on its intracellular domain, creating a high-affinity binding site for arrestin proteins. Arrestin binding sterically prevents the receptor from coupling to its Gs protein, blocking further adenylyl cyclase stimulation and reducing cyclic adenosine monophosphate production even when albuterol is bound. Continued overuse leads to receptor internalization and downregulation, further reducing receptor density on the cell surface. Clinically, this desensitization is a warning sign: overuse of rescue inhalers signals uncontrolled disease requiring step-up of anti-inflammatory maintenance therapy. Cyclic adenosine monophosphate is not stored or depleted. Receptor type conversion and alpha-1 upregulation in the airway do not occur through this mechanism.

Correct Answer

B — Dry mouth, urinary retention, mydriasis, and reduced gastrointestinal motility due to non-selective muscarinic blockade at glands, bladder, iris, and gut

Rationale

Atropine is a non-selective muscarinic antagonist that blocks all five muscarinic subtypes throughout the body. When given for bradycardia, its effects are not limited to the sinoatrial node. Blockade of M3 receptors at salivary glands reduces secretion, producing dry mouth. Blockade of M3 receptors in the bladder detrusor reduces tone, potentially causing urinary retention — a concern in elderly men with prostatic hyperplasia. Blockade of M3 receptors in the iris sphincter produces mydriasis and cycloplegia. Reduced muscarinic drive to the gastrointestinal tract slows motility. The option describing bronchoconstriction and increased salivation describes what would happen if parasympathetic tone were enhanced, not blocked. Atropine does not activate alpha-1 receptors. Muscarinic receptors throughout the body are affected at standard clinical doses.